Enteric Disease Testing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Bacterial Enteric Diseases, Viral Enteric Diseases, Parasitic Enteric Diseases, Rotavirus, Norovirus), End User (Hospitals & Clinics, Diagnostic Centers, Others), by region, and Competition, 2020-2030F

Market Overview

The Global Enteric Disease Testing Market, valued at USD 4.12 Billion in 2024, is projected to experience a CAGR of 4.87% to reach USD 5.48 Billion by 2030. Enteric disease testing encompasses diagnostic procedures designed to identify infections affecting the gastrointestinal tract, typically caused by bacteria, viruses, or parasites. The global market for these tests is primarily driven by the escalating prevalence of enteric infections worldwide and continuous advancements in diagnostic methodologies. For instance, according to the World Health Organization, 29 countries reported 472,697 cholera cases globally in 2022, alongside 2,348 deaths, highlighting a persistent disease burden.

Further propelling market growth are increasing awareness campaigns, enhanced surveillance initiatives, and the rising demand for rapid and point-of-care testing solutions. However, a significant impediment to market expansion remains the elevated costs associated with developing and implementing advanced diagnostic technologies, which can limit adoption, particularly in resource-constrained settings.

Key Market Drivers

The increasing global burden of enteric infections significantly fuels the demand for diagnostic testing solutions. The widespread prevalence of these infections, often exacerbated by inadequate sanitation and contaminated food or water, necessitates robust surveillance and rapid identification to manage outbreaks and prevent further spread. For instance, according to the CDC's Foodborne Diseases Active Surveillance Network (FoodNet) 2023 Preliminary Data, the incidence of infections from pathogens such as Campylobacter, Cyclospora, Shiga toxin-producing E. coli (STEC), Vibrio, and Yersinia increased in 2023 compared with the 2016–2018 baseline, underscoring a persistent and growing threat. Concurrently, technological innovations in diagnostic testing are transforming the market by offering more accurate, faster, and accessible detection methods, including molecular diagnostics, immunoassays, and point-of-care platforms. In a notable development, according to a press release from NOWDiagnostics, in July 2024, the company secured $22.5 million in Series B financing to accelerate the commercialization of at-home diagnostic tests and develop new innovations, highlighting significant private investment in rapid and point-of-care diagnostic advancements.

The combined impact of escalating infection rates and diagnostic breakthroughs creates a dynamic market environment, driving both the volume and sophistication of tests. This sustained need is further amplified by the critical global challenge of antimicrobial resistance, which demands precise pathogen identification to guide appropriate treatment and preserve antibiotic efficacy. For example, according to the World Health Organization's updated Bacterial Priority Pathogens List (BPPL), released in May 2024, 15 families of antibiotic-resistant bacteria, including Salmonella and Shigella, were identified as critical or high priority, emphasizing the urgent need for advanced diagnostic tools to combat antimicrobial resistance. These interrelated factors collectively propel the expansion of the global enteric disease testing market, necessitating continuous innovation and broader adoption of effective diagnostic strategies.

Download Free Sample Report

Key Market Challenges

The elevated costs associated with developing and implementing advanced diagnostic technologies present a significant impediment to the growth of the Global Enteric Disease Testing Market. These high expenditures directly limit the adoption of sophisticated testing platforms, particularly within healthcare systems operating in resource-constrained environments. Such financial barriers restrict access to accurate and rapid diagnostics, leading to delayed diagnoses and treatment for enteric infections. This directly reduces the market penetration of advanced solutions, as facilities are often compelled to prioritize less expensive, albeit potentially less effective, testing methods.

The substantial capital investment required for these technologies strains healthcare budgets globally. According to the AdvaMed Pulse of the Industry 2023 report, the broader medical technology industry's research and development investment reached US$24.7 billion in 2022. This considerable financial outlay for developing innovative technologies translates into higher acquisition and operational costs for end-users, thereby stifling the expansion of the advanced enteric disease testing segment and hindering overall market progress.

Key Market Trends

Digital health integration within diagnostic workflows is a pivotal trend, streamlining how patient data is collected, shared, and managed. This development connects diagnostic platforms with electronic health records and telehealth systems, enhancing efficiency and accessibility. According to the CDC, in April 2024, over 36,000 healthcare facilities could send electronic case reports, an increase from over 25,000 in early 2023, facilitating quicker public health responses to infectious disease threats. This interconnectivity supports comprehensive patient management and rapid epidemiological surveillance. In April 2025, Rimidi, a digital health company, introduced its Rimidi 2.0 platform, designed to enhance remote patient monitoring and chronic disease management through electronic health record integration, showcasing the industry's shift towards unified digital solutions.

The application of artificial intelligence and machine learning in diagnostics marks a significant transformation, providing advanced analytical capabilities to improve detection accuracy and efficiency. These technologies enable sophisticated pattern recognition in complex diagnostic data, leading to earlier and more precise identification of enteric pathogens. According to the Philips Future Health Index 2024, over half (55%) of healthcare informatics leaders are currently utilizing artificial intelligence for in-hospital patient monitoring, and 47% for preventive care clinical decision support, indicating growing reliance on AI for clinical insights. This integration supports clinical decision-making and predicts disease outbreaks. In January 2025, Japan introduced reimbursement for a computer-aided detection tool for colonoscopy, expected to accelerate artificial intelligence implementation in diagnostic practices, highlighting its increasing clinical acceptance and value.

Segmental Insights

The Bacterial Enteric Diseases Segment is a primary growth driver within the Global Enteric Disease Testing Market. This rapid expansion is largely attributed to the escalating worldwide prevalence of bacterial enteric infections, such as salmonellosis and *Escherichia coli*, which pose a significant public health challenge. Furthermore, the increasing emergence of antibiotic-resistant bacterial strains necessitates highly accurate and timely diagnostic tools to guide effective treatment and antimicrobial stewardship. Consequently, ongoing technological advancements in molecular diagnostics and rapid testing platforms, providing enhanced sensitivity and quicker results, are fueling demand for sophisticated detection methods. Efforts by regulatory bodies, including the European Food Safety Authority, to reinforce food safety standards and enhance disease surveillance further underpin this segment's robust growth.

Regional Insights

North America leads the global enteric disease testing market due to its robust healthcare infrastructure and high consumer awareness regarding enteric infections. The region benefits from substantial investment in advanced diagnostic technologies, including molecular diagnostics, which offer rapid and accurate results. Additionally, the presence of numerous key market players and stringent food safety regulations enforced by bodies like the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) drive the demand for comprehensive testing solutions and product innovation. These factors collectively foster a sophisticated market environment conducive to widespread adoption of enteric disease testing.

Recent Developments

• In February 2025, bioMérieux received U.S. FDA clearance for its new molecular diagnostic test, the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid. This innovative midplex panel is capable of detecting 11 of the most prevalent bacteria, viruses, and parasites associated with gastroenteritis from a single sample, delivering results in approximately one hour. The polymerase chain reaction (PCR) based solution integrates with bioMérieux's BIOFIRE® FILMARRAY® 2.0 and Torch PCR platforms, enhancing the company’s comprehensive offerings for gastrointestinal infection diagnostics.

• In February 2024, bioMérieux established a strategic research collaboration with the U.S. Food and Drug Administration (FDA), specifically with its Center for Food Safety and Applied Nutrition (CFSAN). This partnership aims to advance the development of tools to effectively combat foodborne pathogens, a crucial area within enteric disease testing. Initial projects under this agreement are focused on improving the isolation of Shiga-toxin-producing *E. coli* (STECs), enhancing the detection of *Cyclospora cayetanensis*, and streamlining microbial characterization methods for various foodborne pathogens including *Salmonella* and *Listeria monocytogenes*.

• In February 2024, Fapon, a global life sciences company, showcased its comprehensive IVD solutions at Medlab Middle East. During the event, the company introduced a diverse range of high-performance core raw materials essential for the diagnostics of various diseases, including gastrointestinal infections. Fapon also highlighted its strategic partnership with the China Innovation Center (C.I.C.) at Dubai Chambers, established in 2023. This collaboration is designed to facilitate the introduction of Fapon’s innovative diagnostic technologies and services, thereby contributing to the advancement of the local healthcare industry.

• In January 2024, ELITechGroup launched the CE-IVDR certified GI Bacterial PLUS ELITe MGB® Kit, significantly expanding its in vitro diagnostic portfolio for enteric disease testing. This advanced assay is specifically designed to detect key bacterial pathogens such as *Campylobacter* spp., *Clostridium difficile*, *Salmonella* spp., *Shigella* spp., and *Yersinia enterocolitica*. These pathogens are recognized as major causes of both food and waterborne, and hospital-acquired, gastrointestinal infections. The kit is fully validated for use with the company’s ELITe InGenius and ELITe BeGenius sample-to-result instruments, ensuring precise diagnostics from human stool specimens.

Key Market Players

• Abbott Laboratories Ltd.
• Becton Dickinson & Co.
• Biomerica Inc.
• BioMérieux SA
• Bio-Rad Laboratories, Inc.
• Cepheid
• Coris BioConcept
• DiaSorin S.p.A.
• Meridian Bioscience Inc.
• Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Enteric Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Enteric Disease Testing Market, By Disease Type:

• Enteric Disease Testing Market, By End-User:

• Enteric Disease Testing Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Enteric Disease Testing Market.

Available Customizations:

Global Enteric Disease Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Enteric Disease Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]